Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Enterprise Value (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Enterprise Value for 16 consecutive years, with -$11.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value fell 211.37% to -$11.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$11.3 million, a 211.37% decrease, with the full-year FY2024 number at $11.9 million, up 419.45% from a year prior.
  • Enterprise Value was -$11.3 million for Q3 2025 at Gyre Therapeutics, down from -$9.1 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of $21.4 million in Q1 2025 to a low of -$75.4 million in Q2 2022.
  • A 5-year average of -$13.6 million and a median of -$8.0 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: crashed 484.41% in 2022, then soared 562.23% in 2024.
  • Gyre Therapeutics' Enterprise Value stood at -$46.9 million in 2021, then surged by 117.14% to $8.0 million in 2022, then tumbled by 146.48% to -$3.7 million in 2023, then surged by 419.45% to $11.9 million in 2024, then tumbled by 194.99% to -$11.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Enterprise Value are -$11.3 million (Q3 2025), -$9.1 million (Q2 2025), and $21.4 million (Q1 2025).